/
 Patrick Burchell, PGY-2 June 15, 2016  Patrick Burchell, PGY-2 June 15, 2016

Patrick Burchell, PGY-2 June 15, 2016 - PowerPoint Presentation

olivia-moreira
olivia-moreira . @olivia-moreira
Follow
347 views
Uploaded On 2020-04-04

Patrick Burchell, PGY-2 June 15, 2016 - PPT Presentation

Grand Rounds Stuck in the wrong place CC Sudden vision loss OD HPI 66 yo WM with a complex traumatic dural arteriovenous fistula status post prior motor vehicle accident who underwent repeat embolization with Onyx Ophthalmology was paged to the PACU for sudden vision loss of the ri ID: 775402

artery retinal occlusion onyx artery retinal occlusion onyx wnl embolization central view sagittal vision due ophthalmology ophthalmic sclerosis glabella

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document " Patrick Burchell, PGY-2 June 15, 2016" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Patrick Burchell, PGY-2June 15, 2016

Grand Rounds

Stuck in the wrong place

Slide2

CC:Sudden vision loss ODHPI:66 yo WM with a complex traumatic dural arteriovenous fistula status post prior motor vehicle accident, who underwent repeat embolization with Onyx. Ophthalmology was paged to the PACU for sudden vision loss of the right eye upon awakening.

Patient Presentation

Slide3

Non-adhesive liquid embolic agentEthylene vinyl alcohol (EVOH) Dimethyl sulfoxide (DMSO) Tantalum powder Solidifies from outside to inside5 minutesProlonged injection times compared to N-butyl cyanoacrylate glue

What is Onyx?

Slide4

Past Ocular Hx:Nuclear Sclerosis OU Past Medical Hx:Traumatic dural arteriovenous malformation (DAVF), carotid stenosis, hyperlipidemia, hypertension, GERD, seasonal allergiesPast Surgical Hx:Embolization of DAVF X 3, exploratory laparotomy, left knee repair, right maxilla repair

History (

Hx

)

Slide5

Fam Hx:Aneurysm (sister)Meds:Amlodipine-benzapril 10 mg, Aspirin 325 mg, Pantoprazole 40 mg, Rosuvastatin 20 mgAllergies: NKDASocial Hx:Previous smoker (35 pack years)ROS:+ decreased vision OD; denied pain, flashes, floaters

History (

Hx

)

Slide6

ODOSVA (N sc)Light Perception20/70Pupils5→4mm (sluggish)3+ RAPD OD4→3mmIOP14 mmHg15 mmHgEOMfullfullCVFfull

External Exam

Slide7

Anterior Segment Exam

PLE

OD

OS

External/Lids

WNL

WNL

Conj

/Sclera

WNL

WNL

Cornea

Clear

Clear

Ant Chamber

Formed

Formed

Iris

WNL

WNL

Lens

Nuclear Sclerosis

Nuclear Sclerosis

Slide8

Posterior Segment Exam

FundusODOSOptic NervePallorPink and sharpMaculaCherry red spot, with retinal whitening in the posterior poleWNLVesselsArteries attenuatedWNLPeripheryWNLWNL

Slide9

Cerebral Angiography

Sagittal view of Left Internal Carotid Artery (LICA)

Ophthalmic Artery

Sagittal view of Right Internal Carotid Artery

(RICA); bone window

Ophthalmic Artery

Onyx

Slide10

Cerebral Angiography

Late phase sagittal view of RICA

No choroidal Blush

Late phase sagittal view of LICA

Choroidal Blush

Slide11

Post-operative CT

Onyx

Axial bone window

Slide12

66 yo WM with LP OD and a central retinal artery occlusion status post embolization of a DAVF with Onyx.PlanNo intervention due to the nature of the occlusionNo reversal agent available for OnyxFollow up in Retina Clinic

Assessment/Plan

Slide13

1 week follow up

OD

OS

Slide14

SD-OCT

Slide15

Epidemiology1.9 per 100,000 peopleRisk FactorsMale (1.5X)Increased ageHypertensionDiabetesCarotid artery diseaseSmoking

Central Retinal Artery Occlusion

Slide16

Sudden, painless loss of vision, 1 eyeAfferent pupillary defectFundus appearance Retinal whiteningCherry red spotArterial attenuationHollenhorst plaquesIrreversible damage begins after 97 minutes in primate model5

Presentation

Slide17

Most often due to embolization or thrombosis at the lamina cribosa5% due to vasculitic cause like Giant Cell Arteritis66-80% will have final VA 20/400 or worseNo treatments currently with good evidence of efficacyIntraocular pressure lowering/vasodilationThrombolysis

Causes and Treatment

Slide18

Retrospective case series of 44 patients

Most common injection site was the Glabella (59%)

Autologous fat was more likely to cause diffuse occlusion (86%)

27/44 (61%) had final VA of NLP

Slide19

Glabella

https://

plasticsurgerykey.com

/glabellar-flaps-in-nasal-reconstruction/

Slide20

Most often due to embolization, but can also be vasculiticEvaluate for stroke and other cardiovascular risk factorsCheck ESR, CRP, plateletsNo great treatments at this time Botox your glabella, no filler!

Conclusions

Slide21

Dr. SigfordDr. MugavinDr. Piri

Acknowledgements

Slide22

Leavitt JA, Larson TA, Hodge DO, Gullerud RE. The incidence of central retinal artery occlusion in Olmsted County, Minnesota.Am J Ophthalmol. 2011 Nov; 152(5):820-3.e2.Mehta N, Marco RD, Goldhardt R, Modi Y. Central Retinal Artery Occlusion: Acute Management and Treatment. Current ophthalmology reports. 2017;5(2):149-159. doi:10.1007/s40135-017-0135-2.Sadeh-Gonike Y, Magand N, Armoiry X, et al. Transarterial Onyx Embolization of Intracranial Dural Fistulas: A Prospective Cohort, Systematic Review, and Meta-Analysis, Neurosurgery, Volume 82, Issue 6, 1 June 2018, Pages 854–863Park KH, Kim YK, Woo SJ, et al. Iatrogenic occlusion of the ophthalmic artery after cosmetic facial filler injections: a national survey by the Korean Retina Society. JAMA Ophthalmology. 2014 Jun;132(6):714-23.Hayreh SS, Zimmerman MB, Kimura A, Sanon A. Central retinal artery occlusion. Retinal survival time. Experimental eye research. 2004 March; 78(3): 723-36Retina and Vitreous, AAO, BCSC Section 12, 2017-2018 (132-135).

References

Slide23

4 clinical entitiesNon-arteritic permanent CRAOAmaurosis fugaxNon-arteritic with cilioretinal sparingArteritic CRAO